BridgeMD
Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial
EU CTIS ID: 2023-506512-40-00
What this study is testing
To demonstrate that intraoperative low-dose supplementation of AVP induces a reduction in post-transplant AKI after liver transplantation.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- Any adult patient with a scheduled liver transplantation
- All participants will need to be given clear information about the study and give signed informed consent
- Person affiliated to the Social Security
You likely can't join if
- Super-emergency for liver transplantation or fulminant hepatitis
- Pregnancy or breastfeeding
- Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)
- Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation
- Patient with epilepsy
- Hypersensitivity to arginine-vasopressin and to its excipients
See the full eligibility criteria
- Age ≥ 18 years
- Any adult patient with a scheduled liver transplantation
- All participants will need to be given clear information about the study and give signed informed consent
- Person affiliated to the Social Security
- Super-emergency for liver transplantation or fulminant hepatitis
- Pregnancy or breastfeeding
- Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)
- Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation
- Patient with epilepsy
- Hypersensitivity to arginine-vasopressin and to its excipients
- Patient refusal
- Patients for whom it is impossible to give informed consent (language barrier)
- Adults under guardianship or trusteeship, persons deprived of their liberty
- Patient enrolled in another interventional clinical study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.